AstraZeneca

Lord Kakkar Excerpts

Thursday 6th February 2025 Lords Chamber

[The Minister of State, Department for Science, Innovation and Technology (Lord Vallance of Balham) (Lab)]

Clearly, I understand this area rather well. It is disappointing that the AstraZeneca deal fell through. The deal was first raised in 2020 and was then offered in 2024. Subsequent to that, AstraZeneca changed its mind on how much work it wanted to put into the UK, including reducing the R&D component, which meant that there was a reduction in the offer that came from the Government. I understand that there are a number of reasons why this particular deal fell through, but I also reassure noble Lords that there is a very active programme of attracting investment, including discussions with AstraZeneca which are ongoing on other matters.

[Lord Kakkar (CB)]

My Lords, I draw noble Lords’ attention to my registered interests as chairman of the Office for Strategic Coordination of Health Research. Is the Minister content that His Majesty’s Government are doing enough to support global investment in UK life sciences, not only through fiscal measures but through their own investment in securing the infrastructure and capacity for clinical research in our country and the base for fundamental and translational research in our universities through funding for the National Institute for Health and Care Research and the Medical Research Council? Is the Minister able to reassure us that these matters will be considered very carefully in any future comprehensive spending review?

[Lord Vallance of Balham (Lab)]

I thank the noble Lord for his question. Yes, I am very aware of the need for funding in this area and for attracting external inward investment. The noble Lord may well know that a number of companies have been attracted to the UK recently, such as Eli Lilly, with a big deal of £279 million. Last week, Moderna opened its new facility in Harwell within two years. There is a lot going on in terms of inward investment, and the noble Lord is quite right to point out the importance of both NIHR and MRC funding as part of that process.